Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Medtronic reveals 12 month clinical data for Endeavor stent

Medtronic : 22 October, 2007  (New Product)
Medtronic has presented new 12 month data from the Endeavor IV (E-IV) trial during a main-arena plenary session at the world’s leading scientific congress for interventional cardiologists, TCT 2007 (Transcatheter Cardiovascular Therapeutics).
“Significantly, the results at nine months, which contributed to the recent expert panel recommendation on October 10th for FDA approval of the Endeavor stent, were seen again at 12 months,” said Martin B Leon, MD, founder and chairman emeritus of the Cardiovascular Research Foundation, Professor of Medicine, Columbia University Medical Center (NY), and principal investigator of the Endeavor III and Endeavor IV trials.

“Endeavor IV reached its primary endpoint of TVF (target vessel failure) non-inferiority to the Taxus stent. It was very gratifying to learn that the Endeavor had similar efficacy compared to Taxus for all lesion subsets.”

No statistically significant difference in TLR or TVR versus Taxus at 12 months was observed. Endeavor also demonstrated superior procedural success, as measured by the trial protocol. Furthermore, no cases of Stent thrombosis were reported after six months in the E-IV trial.

Also reported at TCT was a 12-month, interim analysis of the first 1,989 patients enrolled in Endeavor Five (E-Five), a prospective international registry providing a real-world performance and safety evaluation of the Endeavor Stent in markets where it is already commercially available.

The primary endpoint of E-Five is MACE (a composite of Major Adverse Cardiac Events) at 12 months. The interim results of E-Five on nearly 2,000 patients demonstrate further consistency with the preceding clinical trial program. A low rate of MACE (7.0 percent) was observed, as was a low rate of target lesion revascularization (TLR) of 3.8 percent. The complete 12 month results on all 8,260 patients will be presented at EuroPCR in May. Importantly in E-Five, this consistency in performance and safety has also been observed in more complex patients.

For E-Five, 34 percent of the patients had diabetes and 62 percent had complex lesions. Despite this complexity, the safety profile previously observed is reinforced by these data. Cardiac death was observed at only 2.0 percent, myocardial infarction at 1.3 percent and Stent thrombosis of only 1.1 percent.

“These results are tremendous, building upon what was already a substantial body of data demonstrating the clinical effectiveness expected from drug-eluting stents but with a safety profile more commonly associated with their bare-metal Stent predecessors,” said Scott Ward, president of the CardioVascular business at Medtronic.

“Our data indicate that Endeavor will fill an important and unique gap in vascular therapy, and that many thousands of patients will ultimately benefit from Endeavor’s performance characteristics,” Ward added. “Following the panel’s recommendation we are confident of approval before the end of this calendar year.”

TCT 2007 is sponsored by the Cardiovascular Research Foundation.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo